The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings

Ryann E. Shor(Fred Hutch Cancer Center), Cyrus M. Ghajar(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Molecular Oncology
May 31, 2021
Cited by 38


Related Papers